Subtopic Deep Dive

IMP Dehydrogenase Inhibition
Research Guide

What is IMP Dehydrogenase Inhibition?

IMP Dehydrogenase Inhibition targets inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in guanine nucleotide biosynthesis, using transition state analogs and allosteric inhibitors for immunosuppression, antiviral, and anticancer applications.

IMPDH catalyzes IMP to XMP conversion using NAD+ as cofactor (Hedstrom, 1999; 101 citations). Inhibitors like mycophenolate block this pathway selectively in lymphocytes and pathogens. Over 10 key papers span mechanism, isoform selectivity, and resistance (Bottoms et al., 2002; 147 citations).

Curated Papers

Key Challenges

Why It Matters

Mycophenolate mofetil, an IMPDH inhibitor, prevents transplant rejection by depleting guanine nucleotides in T- and B-cells (Hedstrom, 1999). IMPDH targeting enhances cancer immunotherapy by synergizing nucleotide depletion with immune checkpoint blockade (Wu et al., 2022; 175 citations). Pan-cancer dependency on nucleotide metabolism positions IMPDH as a metabolic vulnerability (Mullen & Singh, 2023; 381 citations). Plasmodium falciparum IMPDH offers antimalarial potential amid resistance (Cassera et al., 2011; 147 citations).

Key Research Challenges

Isoform Selectivity

IMPDH1 and IMPDH2 differ in expression and inhibitor sensitivity, requiring precise design (Hedstrom, 1999). Structural subdomain variations complicate targeting (McLean et al., 2004; 99 citations).

Resistance Mutations

Pathogens and cancer cells develop mutations evading inhibitors like mycophenolate (Cassera et al., 2011). Host-pathogen metabolic interference adds complexity (Mehrotra et al., 2014; 104 citations).

Allosteric Inhibition

Catalytic and regulatory domains demand dual-site inhibitors (Hedstrom, 1999). Conserved water in Rossmann folds hinders specificity (Bottoms et al., 2002; 147 citations).

Essential Papers

Nucleotide metabolism: a pan-cancer metabolic dependency

Nicholas J. Mullen, Pankaj K. Singh · 2023 · Nature reviews. Cancer · 381 citations

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy

Huailiang Wu, Yue Gong, Peng Ji et al. · 2022 · Journal of Hematology & Oncology · 175 citations

Abstract Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of nucleotide metabolism, our understanding...

A structurally conserved water molecule in Rossmann dinucleotide‐binding domains

Christopher A. Bottoms, Paul E. Smith, John J. Tanner · 2002 · Protein Science · 147 citations

Abstract A computational comparison of 102 high‐resolution (≤1.90 Å) enzyme‐dinucleotide (NAD, NADP, FAD) complexes was performed to investigate the role of solvent in dinucleotide recognition by R...

Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum

María B. Cassera, Yong Zhang, Keith Z. Hazleton et al. · 2011 · Current Topics in Medicinal Chemistry · 147 citations

Malaria is a leading cause of morbidity and mortality in the tropics. Chemotherapeutic and vector control strategies have been applied for more than a century but have not been efficient in disease...

Pathogenicity of Mycobacterium tuberculosis Is Expressed by Regulating Metabolic Thresholds of the Host Macrophage

Parul Mehrotra, Shilpa Jamwal, Najmuddin Saquib et al. · 2014 · PLoS Pathogens · 104 citations

The success of Mycobacterium tuberculosis as a pathogen derives from its facile adaptation to the intracellular milieu of human macrophages. To explore this process, we asked whether adaptation als...

IMP Dehydrogenase: Mechanism of Action and Inhibition

Lizbeth Hedstrom · 1999 · Current Medicinal Chemistry · 101 citations

Inosine monophosphate dehydrogenase (IMPDH) catalyzes the conversion of IMP to XMP with the concomitant reduction of NAD to NADH. This reaction is the rate-limiting step in guanine nucleotide biosy...

Inosine 5′-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo

Jeremy E. McLean, Nobuko Hamaguchi, Peter Belenky et al. · 2004 · Biochemical Journal · 99 citations

Inosine 5´-monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in the de novo biosynthesis of guanine nucleotides. In addition to the catalytic domain, IMPDH contains a subdomain of unk...

Reading Guide

Foundational Papers

Start with Hedstrom (1999; 101 citations) for core mechanism and inhibition strategies; follow with Bottoms et al. (2002; 147 citations) for structural water role and McLean et al. (2004; 99 citations) for nucleic acid binding.

Recent Advances

Mullen & Singh (2023; 381 citations) on pan-cancer metabolism; Wu et al. (2022; 175 citations) for immunotherapy synergy; Cader et al. (2020; 96 citations) on purine nucleotide cycle.

Core Methods

Transition state analogs, allosteric subdomain targeting, Rossmann fold docking, kinetic analysis of NAD+ reduction (Hedstrom, 1999; Bottoms et al., 2002).

How PapersFlow Helps You Research IMP Dehydrogenase Inhibition

Discover & Search

Research Agent uses searchPapers and exaSearch to find IMPDH inhibition literature, revealing Hedstrom (1999) as a core mechanism paper with 101 citations. citationGraph traces isoform selectivity from McLean et al. (2004; 99 citations) to recent cancer applications. findSimilarPapers expands from Cassera et al. (2011; 147 citations) to antimalarial analogs.

Analyze & Verify

Analysis Agent employs readPaperContent on Hedstrom (1999) to extract transition state analog structures, verified by verifyResponse (CoVe) against isoform data. runPythonAnalysis processes nucleotide binding affinities from Bottoms et al. (2002), with GRADE grading kinetic inhibition models. Statistical verification confirms pan-cancer dependencies in Mullen & Singh (2023).

Synthesize & Write

Synthesis Agent detects gaps in resistance mutation coverage between Mehrotra et al. (2014) and Wu et al. (2022), flagging contradictions in allosteric sites. Writing Agent uses latexEditText for inhibitor mechanism reviews, latexSyncCitations for 10+ papers, and latexCompile for publication-ready manuscripts. exportMermaid diagrams Rossmann fold water networks from Bottoms et al. (2002).

Use Cases

"Analyze IMPDH kinetic data from Hedstrom 1999 with Python for IC50 curves."

Research Agent → searchPapers(Hedstrom IMPDH) → Analysis Agent → readPaperContent → runPythonAnalysis(NumPy/matplotlib IC50 plotting) → matplotlib inhibition curves and Ki values.

"Write LaTeX review on IMPDH isoform selectivity citing McLean 2004."

Synthesis Agent → gap detection(IMPDH isoforms) → Writing Agent → latexEditText(structure-function text) → latexSyncCitations(10 papers) → latexCompile → camera-ready PDF with figures.

"Find code for IMPDH docking simulations from recent papers."

Research Agent → paperExtractUrls(Bottoms 2002) → paperFindGithubRepo → Code Discovery → githubRepoInspect → runnable AutoDock scripts for Rossmann binding sites.

Automated Workflows

Deep Research workflow scans 50+ IMPDH papers via searchPapers → citationGraph → structured report on inhibition mechanisms from Hedstrom (1999). DeepScan applies 7-step analysis: readPaperContent(Cassera 2011) → runPythonAnalysis(Plasmodium pathways) → CoVe verification → GRADE-scored summary. Theorizer generates hypotheses linking nucleotide cycle (Cader et al., 2020) to isoform-specific inhibitors.

Try Doxa for IMP Dehydrogenase Inhibition Research

Frequently Asked Questions

What defines IMP Dehydrogenase Inhibition?

Targeting IMPDH, the rate-limiting enzyme converting IMP to XMP in guanine biosynthesis, with transition state analogs and allosteric inhibitors (Hedstrom, 1999).

What are key methods for IMPDH inhibition?

Transition state analogs mimic XMP oxocarbenium ion; allosteric binding disrupts subdomain cystathionine β-synthase domains (Hedstrom, 1999; McLean et al., 2004).

What are foundational papers?

Hedstrom (1999; 101 citations) details mechanism; Bottoms et al. (2002; 147 citations) analyzes Rossmann water; Cassera et al. (2011; 147 citations) covers Plasmodium targets.

What open problems exist?

Overcoming resistance mutations, achieving IMPDH1/2 selectivity, and minimizing toxicity in cancer immunotherapy (Wu et al., 2022; Mehrotra et al., 2014).